Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

NCT06917079 is registered in ClinicalTrials.gov with TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) as lead sponsor.

NCT NCT06917079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2025
Completion date
September 30, 2029
Enrollment
665 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung carcinoma, crc (colorectal cancer), kras g12a, kras g12c, kras g12d, kras g12s, kras g12v, metastatic colorectal cancer (crc), metastatic non-small lung cell cancer, metastatic pancreatic ductal adenocarcinoma, non-small cell lung cancer, nsclc, pdac - pancreatic ductal adenocarcinoma, solid tumor, adult